Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Polymyalgia Rheumatica Market, and What Factors Will Drive It?
In recent times, the market size for polymyalgia rheumatica has experienced a significant boost. The market, which is expected to be worth $1.28 billion in 2024, is estimated to swell to $1.36 billion by 2025, with a compound annual growth rate (CAGR) of 5.9%. The historical growth of this market is attributable to factors such as increased consciousness among medical care practitioners, the growing application of corticosteroids, the proliferation of specialty clinics, the advent of biological therapies, and the augmentation of healthcare budgets.
In the coming years, the polymyalgia rheumatica market is forecasted to experience robust growth. It is projected to reach $1.72 billion in 2029, with a compound annual growth rate (CAGR) of 6.1%. The predicted growth within this period can be ascribed to factors such as increased use of biologics, precision medicine advancements, expedited drug approvals, wider reimbursements, and growth of clinical trials. In the forecast period, key trends to watch include the emergence of combination therapies, improvements in personalized medicine, progress in precision medicine, the application of electronic health records, and the evolution of biomarkers.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp
Which Factors and External Forces Are Driving Demand in the Polymyalgia Rheumatica Market?
The surge in personalized medicine’s popularity is predicted to boost the polymyalgia rheumatica market’s growth. Personalized medicine, which tailors medical treatment to a person’s genetic profile, lifestyle, and specific health conditions for more effective results, is gaining traction due to advancements in genetic research, increasing patient expectations for individualized treatments, and enhancements in diagnostic technologies. Genetic research has given us a more comprehensive understanding of individual genetic variations, enabling more tailored treatments that target specific genetic markers. By choosing drugs based on a patient’s characteristics, personalized medicine can formulate a more effective and safer treatment plan. To illustrate, the Personalised Medicine Coalition, a U.S-based hospital, and healthcare organization reported in February 2024 that the Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, a substantial increase from six in 2022. As a result, the surge in personalized medicine is a critical factor fuelling the polymyalgia rheumatica market’s growth.
Which Segments in the Polymyalgia Rheumatica Offer the Most Growth?
The polymyalgia rheumaticamarket covered in this report is segmented –
1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics
2) By Route Of Administration: Oral; Intravenous; Subcutaneous
3) By Patient Type: Adult; Geriatric; Periatric
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Polymyalgia Rheumatica Market?# Market?
Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive thePolymyalgia Rheumatica Market’s Growth?
Leading entities in the polymyalgia rheumatica market, like Regeneron Pharmaceuticals, Inc., and Sanofi, are channeling efforts into creating more sophisticated drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and efficient treatment alternatives. These blockers are biological drugs designed to restrain IL-6, a critical inflammatory agent in autoimmune diseases. As a result, these remedies reduce inflammation, enhance symptoms and improve the life quality for PMR patients. Notably, in February 2023, the U.S.-based biotechnology firm, Regeneron Pharmaceuticals, and the French healthcare firm, Sanofi, received approval from the Food and Drug Administration (FDA) for their drug, Kevzara (sarilumab), to treat PMR in adults who have insufficiently responded to corticosteroids or struggle to gradually stop their use. Kevzara, the singular approved biologic for this illness, operates by suppressing IL-6-induced signaling. This approval came after a clinical study demonstrated 28.3% of patients on sarilumab attained sustained remission by the 52nd week compared to 10.3% on a placebo. Kevzara is delivered bi-weekly through subcutaneous injection and has also been approved for treating moderately to severely active rheumatoid arthritis. Presently, the Sanofi stock (SNY) is valued at $54.13 on the NASDAQ.
View the full report here:
https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report
What Are the Key Elements That Define the Polymyalgia Rheumatica Market?
Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects older adults, causing muscle pain and stiffness, particularly in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, leading to difficulty in movement and daily activities.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model